ELEstibaliz Lazaro

Estibaliz Lazaro

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Estibaliz Lazaro has a total of 687 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Impact Of Preconception Counseling On Maternal And Neonatal Outcomes In 337 Prospective Pregnancies In Women With Systemic Lupus Erythematosus (French GR2 Study)

    by Amandine Dernoncourt, Morgane Morain, Véronique Le Guern, Jean Schmidt, Estibaliz Lazaro, Viviane Queyrel, Pauline Orquevaux, Odile Debouverie, Alice Berezné, Alban Deroux, et al.

    Background: Preconception counseling is recommended for women with systemic lupus erythematosus (SLE), but its association with pregnancy outcomes has not been prospectively evaluated. We aimed to assess the association between preconception counseling, adverse pregnancy outcomes, and SLE flares during pregnancy.Methods: We analyzed SLE pregnancies enrolled by 12 weeks of gestation in the prospective French GR2 cohort (2014–2024), continuing beyond 13 weeks, and compared outcomes according to preconception counseling status. The primary endpoint was the occurrence of at least one adverse pregnancy outcome (APO), defined as intrauterine fetal death, placental insufficiency leading to preterm delivery, severe small-for-gestational-age birth, or neonatal death. SLE flares and treatment-related outcomes were also assessed. Risks of APO and SLE flare were analyzed using Kaplan–Meier analyses and Cox proportional hazards models.Findings: Among 337 pregnancies, 251 (74.5%) were preceded by preconception counseling and 86 (25.5%) were not. Pregnancies were more frequently planned after counseling (208/239, 87.0% vs 36/77, 46.8%; p<0.001), treatment adherence was higher, and prednisone dose was lower. APOs occurred in 36/244 (14.8%) pregnancies after counseling versus 19/83 (22.9%) without counseling (p=0.09). After adjustment, counseling was associated with a lower risk of APOs (aHR 0.51 [0.28–0.92]; p=0.026). After exclusion of unplanned pregnancies, preconception counseling remained associated with a lower risk of APOs (aHR 0.43 [0.21–0.91]; p=0.029). SLE flares occurred in 27/225 (12.0%) versus 18/78 (23.1%) pregnancies (p=0.02), and counseling remained associated with a lower risk of flares (aHR 0.53 [0.28–0.99]; p=0.048).Interpretation: Preconception counseling was associated with lower risks of APOs and SLE flares during pregnancy. The association between counseling and a lower risk of APOs persisted after exclusion of unplanned pregnancies, suggesting that it extends beyond pregnancy planning alone. These findings support integrating preconception counseling into routine care for women with SLE planning pregnancy.

  • Open Access

    Maternal and neonatal outcomes in SLE: comparison of 430 pregnancies from the French GR2 study with 1720 pregnancies from French perinatal surveys

    by Amandine Dernoncourt, Jean Schmidt, Gaëlle Guettrot-Imbert, Grégoire Martin De Frémont, Anne Murarasu, Marie Viaud, Camille Le Ray, Estibaliz Lazaro, Tiphaine Goulenok, Alban Deroux, et al.

  • Open Access

    Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis

    by Andréa Boizard-Moracchini, Dhouha Msalbi, Sarah Huot-Marchand, Layla Haymour, Eden Lebrault, John Tchen, Titia Jekel, Gaël Galli, Benoît Brilland, Nathalie Mérillon, et al.

    Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is a severe autoimmune disease that lacks effective targeted therapies. T cell and neutrophil activation are associated with tissue lesions in ANCA-associated vasculitis responsible for the necrotizing vasculitis of small blood vessels. Although the aberrant release of reactive oxygen species (ROS) by neutrophils contribute to the disruption of the endothelial barrier, the underlying molecular mechanisms of this oxidative burst remain unclear. Here, we observe that blood vessels in the inflamed organs of patients with AAV express CD95L, which is cleaved by metalloproteases to release soluble CD95L (sCD95L). sCD95L stimulates ROS production in AAV neutrophils via a caspase-driven mechanism. Proteomic analysis reveals that the deubiquitinase OTULIN is a caspase substrate in sCD95L-exposed neutrophils. Caspase-10 cleaves OTULIN after its aspartates at positions 31 and 54 to unleash the activity of E3 ligase complex LUBAC and trigger mitochondrion-dependent ROS production in AAV neutrophils. Inhibition of the CD95-mediated non-apoptotic signaling abrogates ROS production in AAV neutrophils and alleviates clinical symptoms in AAV and crescentic glomerulonephritis mouse models, indicating that CD95 and CD95L represent attractive molecular targets for patients with AAV.

  • Open Access

    Early methylprednisolone pulses and prevention of long-term damage accrual in active systemic lupus erythematosus: a propensity score analysis of the Lupus–Cruces–Bordeaux cohort

    by Beatriz Marín-García, Luis Dueña-Bartolomé, Diana Paredes-Ruiz, Kima López-Aldabe, Pablo Ortiz-De-Urbina, Estibaliz Lázaro, Guillermo Ruiz-Irastorza

    Objective: Methylprednisolone pulses (MP) help achieve prolonged remission in patients with moderate–severe systemic lupus erythematosus (SLE), but their potential effect in reducing damage accrual has not been addressed. This study aims to disclose whether MP given within the first year of follow-up could impact long-term damage accrual. Methods: Observational study using clinical care data of patients included in the Lupus–Cruces–Bordeaux cohort, expanded with patients from the historic Lupus Cruces cohort, with a follow-up time ≥5 years and up to 10 years. The primary outcome was the presence of irreversible organ damage or death for any cause during the whole follow-up time; the early outcome was set at 5 years. In addition, specific SLE-related and GC-related, cardiovascular and other forms of damage were also assessed as outcomes. The effect of MP was evaluated by Kaplan-Meier survival curves and propensity score (PS)-adjusted Cox models, in the whole cohort and in groups of mild activity (Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) <6) and moderate–severe activity (SLEDAI≥6). Results: 469 patients were included, of whom 99 (21%) received MP. In the PS-adjusted Cox models, MP was associated with a significantly reduced risk for the primary outcome (adjusted HR 0.63, 95% CI 0.40 to 0.98, p=0.044), with the effect being significant also at 5 years (adjusted HR 0.61, 95% CI 0.37 to 0.98, p=0.042). The stratified analyses revealed that the benefit was restricted to the group of patients with moderate/severe activity and mainly in lupus and glucocorticoid-related damage items. Conclusions: This study supports the role of the early MP in reducing long-term damage accrual and death, especially among patients with moderate/severe activity.

  • Open Access

    Efficacy of the Lupus-Cruces Nephritis protocol in different prognostic groups: a propensity score and cluster analysis

    by Guillermo Ruiz-Irastorza, Beatriz Marín-García, Luis Dueña-Bartolomé, Diana Paredes-Ruiz, Amaia Osorio, Estibaliz Lázaro

    Objective: To assess the efficacy of the Lupus-Cruces Nephritis (LCN) protocol vs standard of care (SOC) in achieving complete vrenal response (CRR) among different subpopulations and clinical clusters of patients with LN. Methods: This was an observational comparative study with clinical care data of patients from the Lupus-Cruces, historic Lupus-Cruces and Lupus-Bordeaux cohorts. Different prognostic factors were obtained from previous studies and analysed in both LCN and SOC groups. Three different clinical clusters of patients were identified using a two-way clustering analysis. A multivariate propensity score (PS) adjusted analysis and Cox proportional hazards analysis were performed comparing both therapeutic schemes in the different identified subpopulations and clusters. Results: Within the cohort of 147 patients, those receiving the LCN protocol (40/47, 85%) were more likely to achieve CRR at 12 months than patients receiving the SOC (44/100, 44%). This was consistent across all prognostic subpopulations. The PS-adjusted logistic regression by subgroups confirmed these results. Three different clusters (named C1, C2 and C3) were identified. Both the univariate and the PS-adjusted Cox regression analysis for CRR at any time confirmed the higher likelihood of achieving CRR of patients treated with the LCN protocol in the three clusters: C1, hazard ratio (HR) 10.7 (95% CI 1.65–69.6, P = 0.013); C2, HR 2.2 (95% CI 1.16–4.1, P = 0.016); C3, HR 6.1 (95% CI 2.99–12.51, P < 0.001). Conclusion: The LCN protocol was superior to the SOC schemes in achieving CRR in patients with LN across different subpopulations and clinical clusters.

  • Open Access

    Relapse risk of lupus-related serositis according to immunosuppressive therapy: a national real-world study

    by Elodie Fels, Cassandra Goncalves, Sandrine Jousse-Joulin, Laurent Chiche, Anne-Sophie Korganow, Thierry Martin, Laurent Arnaud, Sebastien Ottaviani, Estibaliz Lazaro, Jean Sibilia, et al.

    Background: Management of systemic lupus erythematosus (SLE) is largely guided by organ involvement. Serositis affects up to 46% of patients, yet its treatment is mainly empirical and extrapolated from other manifestations, and long-term outcome data remain limited. We aimed to evaluate short-term response to anti-inflammatory therapy and to examine associations between immunosuppressive treatments and serositis relapse. Methods: We conducted a multicentre retrospective real-world study in patients with SLE with pericarditis and/or pleuritis, identified through a nationwide call for case reporting. Initial response was defined as symptom and sign resolution at early reassessment. Relapse was defined as recurrence requiring treatment intensification ≥3 months after the index flare. Relapse-free survival was described by Kaplan–Meier methods and analysed as recurrent events using a Prentice-Williams-Peterson gap-time Cox model adjusted for prespecified confounders. Results: One hundred patients contributed 180 serositis episodes (161 pericarditis, 51 pleuritis, associated in 32 cases) over a mean follow-up of 91 months; 46% experienced ≥1 relapse. Overall, 108/124 (87.1%) of evaluable episodes responded to initial anti-inflammatory therapy, with no significant difference between corticosteroid-based and aspirin/colchicine regimens. Corticosteroid use was not associated with increased relapse risk (46.0% vs 46.2%, p=0.98). Conventional immunosuppressants (methotrexate, azathioprine, mycophenolate mofetil) were not associated with reduced relapse risk, whereas belimumab was associated with lower relapse risk (HR=0.34, 95% CI 0.14 to 0.84; p=0.019). Conclusion: Lupus-related serositis is frequent and highly relapsing. In this national cohort, belimumab—but not conventional immunosuppressants—was associated with reduced serositis recurrence, supporting its further evaluation in lupus serositis.

  • Open Access

    A Pragmatic First-Line Screening Assay for PDGFR Rearrangements: A Real-World Clinical Validation

    by Floriane Lanneretonne, Lisa Boureau, Marina Migeon, Claudine Chollet, Mélanie Martin Gourier, Diane Lara, Chloé Benard, Gabriel Etienne, Wendy Cuccuini, Laurie Monier, et al.

    Myeloid/lymphoid neoplasms with tyrosine kinase rearrangements (MLN-TKs) are rare clonal eosinophilias driven by PDGFRA, PDGFRB and other kinase fusions, highly sensitive to tyrosine kinase inhibitors. Their detection remains challenging, particularly for cryptic PDGFRA rearrangements. We performed a large multicenter real-world validation of the generic quantitative RT-PCR assay (gPDGFR), which detects 3′ PDGFRA/PDGFRB overexpression independently of fusion partner. A total of 231 consecutive patients with hypereosinophilia from 12 French centers were analyzed, and assay robustness was further assessed in an independent heterogeneous cohort of 102 tyrosine kinase inhibitor (TKI)-treated patients. Twenty-two PDGFR-rearranged cases (14 PDGFRA-r, 8 PDGFRB-r) were identified. The assay demonstrated 100% sensitivity and 100% negative predictive value. For PDGFRA, positive predictive value and specificity reached 100%. In contrast, PDGFRB overexpression showed lower specificity due to borderline false-positive cases, underscoring the need for confirmatory testing. In selected patients, longitudinal gPDGFR kinetics paralleled fusion-specific RT-qPCR, supporting its use for molecular follow-up when dedicated assays are unavailable, although it does not provide quantitative measurable residual disease assessment. Overall, gPDGFR represents a robust, partner-independent first-line screening strategy that can be readily integrated into routine diagnostic workflows to enable timely identification of patients eligible for targeted therapy.

  • Open Access

    Real‐world use of second‐generation integrase strand transfer inhibitors ( INSTI ) as switch therapy in the prospective ANRS ‐ CO3 ‐ AquiVIH ‐ NA cohort

    by O. Leleux, A. Peyrouny‐Mazeau, A. Perrier, M. Hessamfar, G. Le Moal, D. Neau, L. Alleman, C. Cazanave, E. Lazaro, P. Duffau, et al.

    Objectives: To characterize real‐world treatment switching in France to bictegravir (BIC or B) or dolutegravir (DTG)‐based regimens with a focus on treatment persistence, effectiveness (HIV‐1 RNA ≤50 copies/ml) and particular attention to the prevalence and incidence of comorbidities. Methods: People living with HIV from the prospective ANRS‐CO3‐AquiVIH‐NA cohort, who switched from effective antiretroviral treatment (ART) to a BIC‐ or DTG‐based regimen between 2018 and 2021, were eligible for analysis. Results: A total of 2275 people living with HIV were included (52% receiving B/F/TAF, 8% DTG/3TC/ABC, 18% DTG/RPV, 22% DTG/3TC) with a median age of 53–56 years and a comorbidity prevalence of 71%–75% across treatment groups (chronic kidney disease (CKD) 15%–25%, diabetes mellitus 15%–19%, hypertension 57%–64%). Viral suppression rates at month 18 (LOCF, last observation carried forward) using a missing‐equals‐excluded (M = E) approach were 97% on B/F/TAF, 95% on DTG/3TC/ABC, 97% on DTG/RPV and 96% on DTG/3TC. Discontinuation rates were 16.5% for B/F/TAF, 37.5% for DTG/3TC/ABC, 16.7% for DTG/RPV and 17.3% for DTG/3TC, driven by adverse events in 5.6%, 12.5%, 5.6% and 6.1%, respectively. Comorbidity incidence rates/1000 person years in those free of the respective disease were 39 for hypertension, 22 for diabetes mellitus, 13 for cardiovascular events and 5 for CKD. Conclusions: In this real‐world cohort, treatment persistence 18 months after therapy switch was similar for B/F/TAF, DTG/RPV and DTG/3TC, but significantly lower for DTG/3TC/ABC. All regimens maintained high levels of viral suppression. Furthermore, the cohort illustrates the disease burden experienced by middle‐aged and elderly people living with HIV and highlights the importance of adapting ART to the specific needs of this population.


  • Open Access

    A Pragmatic First-Line Screening Assay for PDGFR Rearrangements: A Real-World Clinical Validation

    by Floriane Lanneretonne, Lisa Boureau, Marina Migeon, Claudine Chollet, Mélanie Martin-Gourier, Diane Lara, Chloé Benard, Gabriel Etienne, Wendy Cuccuini, Laurie Monier, et al.

    Myeloid/lymphoid neoplasms with tyrosine kinase rearrangements (MLN-TK) are rare clonal eosinophilias driven by PDGFRA, PDGFRB and other kinase fusions, highly sensitive to tyrosine kinase inhibitors. Their detection remains challenging, particularly for cryptic PDGFRA rearrangements. We performed a large multicenter real-world validation of the generic quantitative RT-PCR assay (gPDGFR), which detects 3′ PDGFRA/PDGFRB overexpression independently of fusion partner. A total of 231 consecutive patients with hypereosinophilia from 12 French centers were analyzed, and assay robustness was further assessed in an independent heterogeneous cohort of 102 TKI-treated patients. Twenty-two PDGFR-rearranged cases (14 PDGFRA-r, 8 PDGFRB-r) were identified. The assay demonstrated 100% sensitivity and 100% negative predictive value. For PDGFRA, positive predictive value and specificity reached 100%. In contrast, PDGFRB overexpression showed lower specificity due to borderline false-positive cases, underscoring the need for confirmatory testing. In selected patients, longitudinal gPDGFR kinetics paralleled fusion-specific RT-qPCR, supporting its use for molecular follow-up when dedicated assays are unavailable, although it does not provide quantitative measurable residual disease assessment. Overall, gPDGFR represents a robust, partner-independent first-line screening strategy that can be readily integrated into routine diagnostic workflows to enable timely identification of patients eligible for targeted therapy.

  • Open Access

    Stool Screening for Campylobacter Species in Hypogammaglobulinemic Patients Receiving Immunoglobulin Therapy

    by Basile Mechernene, Philippe Lehours, Etienne Rivière, Noémie Gensous, Claire Tinévez, Pierre Duffau, Félix Blaison, Camille Prot-Leurent, Thomas Pires, Carine Greib, et al.

    Hypogammaglobulinemia (HG) predisposes patients to gastrointestinal Campylobacter infections. This prospective study determined the prevalence of Campylobacter in stool samples from patients with immunoglobulin (Ig)-substituted HG at Bordeaux University Hospital. 73 patients (42 women, median age: 61) receiving Ig substitution therapy were enrolled from July 2022 to July 2024. Stool samples were analysed with culture, PCR, faecal calprotectin levels, and immune profiles were also assessed. A second stool sample was collected from 38 patients after 6–12 months, totalling 111 samples. 53 patients had primary HG (32 common variable immunodeficiency, 7 IgG subclass deficiencies, 4 Bruton’s agammaglobulinemias) and 20 had secondary HG (7 drug-induced, 8 lymphoid hemopathy-related, 5 mixed). Campylobacter were detected in 11 patients (15.1%), with species identified as Campylobacter jejuni, Campylobacter coli, and Aliarcobacter butzleri. Diarrhea was reported in 42% of Campylobacter-positive patients versus 15% of negative patients. Campylobacter-positive patients exhibited higher median faecal calprotectin levels (255 µg/g vs. 52 µg/g). Among positive patients, 44% (versus 34% in negative patients) had non-infectious complications such as immune complications. Mean residual IgG levels were similar between groups, although IgA and IgM were lower in Campylobacter-positive patients (0 vs. 0.36 g/L and 0.17 vs. 0.40 g/L, respectively). The mean CD4/CD8 ratio was also lower in the positive group (1.71 ± 0.85 vs. 2.06 ± 1.18). This study reveals a high prevalence of Campylobacter in HG patients despite receiving Ig therapy. Elevated faecal levels of calprotectin in symptomatic patients suggests active infection. Screening for Campylobacter should be considered in HG patients presenting with digestive symptoms.